Breakthrough Study Reveals How Three Proteins Shield the Liver from Deadly Disease

Scientists have uncovered a key molecular pathway that controls liver disease in male mice. The discovery centres on a trio of proteins—SIRT3, DsbA-L, and TFAM—which work together to prevent metabolic dysfunction-associated steatohepatitis (MASH). Their findings suggest new ways to diagnose and treat the condition by targeting mitochondrial health. The study reveals that mitochondrial damage lies at the heart of MASH progression. When the SIRT3-DsbA-L-TFAM axis functions properly, it maintains mitochondrial integrity and stops the release of DNA into the cell. This prevents the activation of cGAS, a protein that triggers harmful inflammation.

Disrupting any part of this axis—whether SIRT3, DsbA-L, or TFAM—led to severe consequences in mice. Mitochondrial DNA became unstable, leaking into the cytosol and activating cGAS. As a result, pro-inflammatory signals surged, and liver damage worsened.

Researchers also tested potential treatments. Restoring TFAM levels or boosting SIRT3 activity with drugs reversed mitochondrial defects in the mice. Inflammation dropped, and liver function improved.

The work highlights a close link between metabolism and immunity. Mitochondria act as a critical meeting point, where energy production and immune responses intersect. Changes in SIRT3, DsbA-L, or TFAM could even serve as early warning signs for MASH. These findings open doors for new MASH therapies. Drugs that activate SIRT3 or stabilise mitochondrial transcription might slow or stop disease progression. Beyond liver conditions, the same molecular pathway could play a role in other metabolic and degenerative disorders.